[ad_1]
Duan Jingyuan / Text
According to the notice from the National Health Insurance Administration, the new version of the health insurance catalog was officially implemented on March 1, and the 2019 health insurance catalog will also be invalidated simultaneously.
On December 28, 2020, the National Health Insurance Administration officially announced the 2020 version of the health insurance catalog. The new drug catalog contains a total of 2,800 Western drugs and Chinese patented drugs, including 1,264 Western drugs, 1,315 Chinese patented drugs, and 221 drugs traded during the agreement period. In addition, there are 892 kinds of Chinese medicine decoction pieces that the fund can afford.
It is understood that the 221 drugs in the new version of the agreement period of the medical insurance drug catalog come mainly from the medical insurance negotiations in 2019 and 2020. Among them, the drug contract included in the medical insurance negotiation in 2019 will be valid until December 31, 2021, and the drug agreement included in the 2020 health insurance negotiation will be valid for two years until December 31, 2022. There are 221 drugs negotiated, including 162 Western drugs, including 45 antitumor drugs, 117 other Western drugs and 59 Chinese patented drugs.
After the 2020 health insurance negotiations, a total of 119 drugs were successfully negotiated, of which 23 were transferred directly and 96 exclusive drugs were negotiated. The negotiation success rate reached 73.46% and the average price of successfully negotiated drugs decreased by 50.64%.
Since the beginning of the health insurance negotiations, the access and pricing of PD- (L) 1 has attracted much attention. Xiong Xianjun, Director of the Department of Medical Services of the National Medical Security Administration, previously publicly stated that seven PD- (L) 1 products participated in the negotiation this year, and that the negotiations for three PD-1 products of domestic manufacture were successful. and the price reduction was still very large, around 80%. “The amount of PD-1 listed on the market is relatively large and there is strong competition between companies. Therefore, in addition to considering the clinical efficacy of PD-1, the most important thing is to consider the degree of competition in market. The reserve price of medicines. “
Currently, prices for the three PD-1 models from Junshi Bio, BeiGene and Hengrui Pharmaceuticals have been announced for inclusion in the health insurance catalog.
According to public information, BeiGene tislelizumab has two indications included in the medical insurance, including the treatment of relapsed or refractory classical Hodgkin lymphoma (R / R cHL) and urothelial carcinoma (UC) of locally advanced or metastatic disease. The new price before the health insurance reimbursement is reported to be 2,180 yuan / bottle (100 mg), the annual treatment fee is about 75,000 yuan, and the price has been reduced by 80%. Prior to this, Junshi Bio president Xiong Jun appeared in the official video and also allowed the price of 80 mg of teriplizumab to flow earlier, a decrease of about 70.8% to 906.08 yuan per tube. Teriprizumab is the first independently developed PD-1 monoclonal antibody in China. Currently, only indications for melanoma are included in health insurance. The price of Hengrui Medicine’s Carrelizumab has emerged from multiple sources the night of the end of the health insurance negotiations. Public information shows that the price of Carrelizumab 200 mg after entering health insurance is about 3,000 yuan, a drop. About 84.85%. Currently, the four indications for Karelizumab are included in the insurance list, namely Hodgkin lymphoma, liver cancer, non-small cell lung cancer, and squamous cell carcinoma of the esophagus.
Just the day before, Junshi Bio and AstraZeneca jointly announced that they had reached deep cooperation. Junshi Bio will grant the right to promote the injection of AstraZeneca Teriplimumab in the secondary markets of mainland China, as well as subsequent approvals. Exclusive national right to promote the listed indications for urothelial cancer. Junshi Bio will continue to be responsible for promoting the main teriplimumab market in mainland China for approved indications for urothelial cancer.
There was a voice from Junshi Biology, hoping to use AstraZeneca’s extensive network of channels accumulated in China, especially its promotional ability in the county market, to promote teriprizumab to open up the Chinese market. Judging by Junshi Bio’s “heads up” with AstraZeneca, it is certainly a “breakthrough” in the context of fierce competition in the industry, trying to push the canal to sink and open up the county market.
In addition to further intensifying the “deep digging” of the domestic market, as competition becomes more “daily”, the domestically produced PD- (L) 1 “goes to sea” to achieve the license before and after the Competition in this field is further extended to the overseas market. According to news a few days ago, Junshi Biosciences and Coherus BioSciences have reached a cooperation for the development and commercialization of the injectable Teriplizumab monoclonal antibody drug in the United States and Canada; BeiGene authorized $ 2.2 billion tislelizumab at Novartis; and previously, Cinda BioSintilimab was also licensed to Eli Lilly for $ 1 billion.
[Autor: Duan Jing Yuan] (Edit: Duan Jingyuan)
Keywords:
